Last reviewed · How we verify
NCT04962438
Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function
trial testing Anti-VEGF in Cardiac Toxicity in 30 participants. Status unknown.
1 December 2021
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 5 July 2019 |
| Primary completion | 1 December 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anti-VEGF (anti-vegf) — full drug profile →
Conditions studied
- Cardiac Toxicity — all drugs for Cardiac Toxicity →
- VEGF — all drugs for VEGF →
- Endothelial Dysfunction — all drugs for Endothelial Dysfunction →
Sponsor
Peking University Third Hospital
Who can join
Eligibility, any sex, with Cardiac Toxicity or VEGF. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Explore the effects of anti-VEGF targeted drugs on blood pressure and endothelial function in cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04962438
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-VEGF
Trials testing the same drug.
- NCT07062055 — BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases · Phase 2 · recruiting
- NCT06537908 — Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC · recruiting
- NCT04626128 — Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD · Phase 1, PHASE2 · completed
- NCT04171141 — Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestin · Phase 1 · terminated
- NCT03699618 — Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration · terminated
Other recruiting trials for Cardiac Toxicity
Currently open trials in the same condition.
- NCT06664528 — Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies · recruiting
- NCT05559164 — Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted · Phase 2 · recruiting
- NCT06277388 — Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment. · active not recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04962438 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 15 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04962438.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing